Hybrid closed loop technology was associated with superior efficacy and safety outcomes relative to standard insulin therapy in T1D.

The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

Q1 2025 Earnings Call Transcript February 6, 2025 Embecta Corp. beats earnings expectations. Reported EPS is $0.65, ...

Having a 'moon face' can be a sign of Cushing syndrome, but that's typically not the only symptom. Here's what experts want ...

CIRM awards US$ 4 mn grant to Entos Pharma to advance development of ENTLEP001, a durable and redosable genetic medicine to treat CGL: San Diego Friday, February 7, 2025, 15:00 Hr ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use ...

EVA Pharma of Africa, DNA Script and Quantoom Biosciences have signed a memorandum of understanding (MoU) to establish the first digital-to-biologics, end-to-end mRNA production platform in Egypt. It ...